ClinicalTrials.gg

Program

Olvimulogene nanivacirepvec

Also written as “GL-ONC1” and “Olvi-Vec”.

Its studies are mostly in Ovarian Neoplasms · Carcinoma, Non-Small-Cell Lung · Peritoneal Neoplasms · Neoplasms · Head and Neck Neoplasms, led by 3 companies.

Furthest: phase 2, since Apr 25, 20166 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Genelux31 open or runningphase 2since Apr 25, 2016Apr 22, 2012Feb 2027phase 2 · NCT06463665
Genelux20 open or runningphase 2since Sep 20, 2011Nov 18, 2008none ahead
Newsoara HYK Biopharmaceutical (Shanghai)11 open or runningphase 2since Jul 2, 2025Jul 2, 2025Dec 2026phase 2 · NCT07136285

Also a collaborator on its studies: Newsoara Biopharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 18, 2008First study: phase 1 study in NeoplasmsNew to GeneluxGenelux · NCT00794131 · 43 enrolled · United Kingdom
  2. Sep 20, 2011Phase 2 study in Peritoneal NeoplasmsGenelux · NCT01443260 · 9 enrolled · Germany
  3. Apr 22, 2012Genelux's first study: phase 1 study in Head and Neck NeoplasmsNew to GeneluxGenelux · NCT01584284 · 19 enrolled · United States
  4. Apr 25, 2016Phase 2 study in Ovarian NeoplasmsGenelux · NCT02759588 · 46 enrolled · United States
  5. Jun 11, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungGenelux · NCT06463665 · 142 planned · United States
  6. Jul 2, 2025Newsoara HYK Biopharmaceutical (Shanghai)'s first study: phase 2 study in SCLC, Extensive StageNew to Newsoara HYK Biopharmaceutical (Shanghai)Newsoara HYK Biopharmaceutical (Shanghai) · NCT07136285 · 27 planned · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in SCLC, Extensive StageNewsoara HYK Biopharmaceutical (Shanghai) · NCT07136285
  2. Feb 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungGenelux · NCT06463665

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07136285SCLC, Extensive Stage · China2RecruitingNewsoara HYK Biopharmaceutical (Shanghai)Dec 202627
NCT06463665Carcinoma, Non-Small-Cell Lung · United States2RecruitingGeneluxFeb 2027142
NCT02759588Ovarian Neoplasms · United States2CompletedGeneluxDec 31, 202146
NCT01584284Head and Neck Neoplasms · United States1CompletedGeneluxJun 201519
NCT01443260Peritoneal Neoplasms · Germany2CompletedGeneluxSep 20149
NCT00794131Neoplasms · United Kingdom1CompletedGeneluxNov 201543

How it is read

Names in the registry

  • “GL-ONC1”, 3 entries
  • “Olvi-Vec”, 2 entries
  • “Olvimulogene nanivacirepvec”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.